Crinetics Pharmaceuticals, Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. (CRNX)
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 114,341 | 101,536 | 110,901 | 53,726 |
| Restricted cash | NaN | 0 | 500 | 500 |
| Investment securities, amortized cost of 979,147 at march 31, 2026 and 924,317 at december 31, 2025 | 1,176,965 | 926,353 | 981,390 | 1,142,634 |
| Trade accounts receivable, net | 5,683 | 592 | NaN | NaN |
| Inventory | 3,064 | 2,022 | NaN | NaN |
| Prepaid expenses and other current assets | 22,361 | 17,839 | 28,484 | 20,404 |
| Total current assets | 1,322,414 | 1,048,342 | 1,121,275 | 1,217,264 |
| Property and equipment, net | 13,497 | 14,296 | 14,377 | 14,670 |
| Operating lease right-of-use assets | 39,790 | 40,492 | 41,147 | 41,902 |
| Restricted cash, net of current portion | 800 | 800 | 800 | 800 |
| Prepaid expenses and other assets, net of current portion | 24,822 | 22,327 | 18,432 | 14,938 |
| Total assets | 1,401,323 | 1,126,257 | 1,196,031 | 1,289,574 |
| Deferred revenue | NaN | NaN | 1,642 | 1,904 |
| Accounts payable and accrued expenses | 37,487 | 41,770 | 33,674 | 38,086 |
| Accrued compensation and related expenses | 25,792 | 35,578 | 32,398 | 21,796 |
| Deferred revenue | 1,271 | 1,235 | NaN | NaN |
| Operating lease liabilities | 6,536 | 6,489 | 6,441 | 6,610 |
| Total current liabilities | 71,086 | 85,072 | 74,155 | 68,396 |
| Operating lease liabilities, non-current | 41,319 | 42,052 | 42,703 | 43,326 |
| Deferred revenue, non-current | 3,346 | 3,810 | 4,110 | 3,992 |
| Other liabilities | 4,926 | 3,240 | 2,894 | 2,334 |
| Total liabilities | 120,677 | 134,174 | 123,862 | 118,048 |
| Common stock and paid-in capital, 0.001 par 200,000 shares authorized 94,548 shares issued and outstanding at march 31, 2026 95,575 shares issued and outstanding at december 31, 2025 | 2,828,204 | 2,407,757 | 2,364,699 | 2,334,538 |
| Stock held in trust | NaN | NaN | NaN | 112 |
| Accumulated other comprehensive (loss) income | -1,254 | 1,865 | 2,194 | 1,621 |
| Accumulated deficit | -1,545,272 | -1,417,427 | -1,294,612 | -1,164,521 |
| Stock held in trust | 1,032 | 112 | 112 | NaN |
| Total stockholders equity | 1,280,646 | 992,083 | 1,072,169 | 1,171,526 |
| Total liabilities and stockholders equity | 1,401,323 | 1,126,257 | 1,196,031 | 1,289,574 |